Premier Perspectives The blog for insider insights in clinical development Recent Posts By expertise area All expertise areas Medical DeviceRare DiseaseOncology & HematologyDiagnosticsDigital TherapeuticsMedTechPediatricsNeuroscienceAnalgesiaDermatologyOtherCOVID-19Cell & Gene TherapyWomen's HealthReal-World & Late PhaseLife at Premier By functional area All functional areas Development StrategyClinical Research: Phase 1 - Phase 4ConsultingData Management & BiostatisticsFunctional Service Provider (FSP)Global ComplianceMedical and Regulatory AffairsPatient and Stakeholder EngagementProject ManagementQualityReal-World Science and Late PhaseSafety/PharmacovigilanceStudy DesignStudy Start-UpOtherCOVID-19Product Development Clinical ResearchPhase 1 - Phase 4 Leveraging Technology and Expert Clinician Review to Enhance Risk Detection in Neuroscience Studies By Andreas Schreiner October 16, 2023 Clinical ResearchPhase 1 - Phase 4 What Patient Population is Participating in Your Early-Phase Gene Therapy Trials? These Factors Could Influence Your Strategy By Kenneth Ndugga-Kabuye September 6, 2023 Consulting Orphan Drug Designation: When Is It Appropriate, and How Does It Apply to Orphan Subsets? By Vanessa Atayde September 5, 2023 Clinical ResearchPhase 1 - Phase 4 The Multi-Faceted World of Clinical Trial Matching in Precision Oncology Studies By Premier Research September 1, 2023 Clinical ResearchPhase 1 - Phase 4 Where Biomarkers and Gene Therapy Trials Intersect: Benefits Abound By Kenneth Ndugga-Kabuye September 1, 2023 Clinical ResearchPhase 1 - Phase 4 A Different Pace: Meeting the Demands of Liquid Biopsy Development for Early Cancer Detection By Charles Chrisawn July 18, 2023 Previous 1 …4 5 6 7 8 … 57 Next × ALSO OF INTERESTKey Considerations When Designing a Phase 1...Nostalgia or Shell Shock? Assessing PTSD Is a...Gene Therapy 101: From the 1960s to Today